TEVA (TEVA) provides an update on a Phase III trial for Milprosa: 1) further evidence that the
Teva provides an update on a Phase III trial for Milprosa: 1) further evidence that the ring ``is comparable to progesterone gel in efficacy''; 2) at eight weeks, multiple pregnancy rates were higher for those treated with Milprosa compared to gel; 3) multiple live birth rates were higher with Milprosa.
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced recently that they have signed a definitive agreement under which Teva will acquire Barr, the fourth largest generic drug company worldwide.